Clinically, CTD-ILD/IPAF are more often treated with systemic corticosteroids and other immunosuppressants that suppress airway iNOS and lower FeNO [40,41,42], whereas IPF is typically managed with antifibrotics without maintenance immunosuppression. The gene discussed is NOS2; the disease is interstitial lung disease.